消除喘息:重症哮喘的新型治疗靶点
本文回顾了自2003年奥马珠单抗获批以来针对2型高表达重症哮喘的生物制剂治疗格局,包括IL-5、IL-5受体和IL-4受体拮抗剂,并指出部分患者存在无初始应答、无法耐受不良反应或随时间失去治疗应答的问题,进而引出本系列文章讨论的三种治疗重症2型高表达哮喘的新方法。
要点
- 抗IL-5、IL-5受体及IL-4受体单抗已拓宽2型高表达重症哮喘的治疗选择。
- 部分重症哮喘患者对现有生物制剂无初始应答、不能耐受或随时间失去应答。
- 本系列文章将讨论三种治疗重症2型高表达哮喘的新方法。
核心结论
- 现有靶向2型炎症的生物制剂虽有效,但部分重症哮喘患者仍存在无应答、不耐受或应答丧失的问题,需探索新治疗靶点。
主要发现
- 自2003年奥马珠单抗获FDA批准以来,针对2型高表达哮喘的靶点新增了IL-5拮抗剂(美泊利珠单抗、瑞利珠单抗)、IL-5受体拮抗剂(贝那利珠单抗)和IL-4受体拮抗剂(度普利尤单抗)。
- 这些药物显示出显著疗效,但部分重症哮喘患者无初始应答、不能耐受不良反应或随时间失去治疗应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2003, the first biologic therapy (omalizumab) for asthma was U.S. Food and Drug Administration approved and immediately revolutionized the treatment of patients with severe asthma, including patients with evidence of type 2 (T2) inflammation. In the years since approval, additional monoclonal antibodies against T2-high asthma targets have widened the therapeutic landscape and include antagonists to IL-5 (mepolizumab and reslizumab), the IL-5 receptor (benralizumab), and the IL-4 receptor (dupilumab). These medications have shown considerable efficacy, yet some patients with severe asthma have no initial response, cannot tolerate the adverse reactions, or lose therapeutic response with time. Although there are many medications in development to improve asthma management, the following articles outline three new promising and not-so-promising approaches for the treatment of severe T2-high asthma.
引用
- Ramonell RP, Runnstrom MC, Yang P, et al. Wiping Out Wheezing: Novel Therapeutic Targets for Patients with Severe Asthma. Am J Respir Crit Care Med. 2020. PMID: 33052701. doi:10.1164/rccm.202005-1797RR
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。